Diss. (sammanfattning) Stockholm : Karolinska institutet, 2009.

Thesis (Ph. D.)--University of Washington, 2003. / Vita. Includes bibliographical references (leaves 124-147).

Vitamin D3 must be metabolically activated by the liver to 25-hydroxyvitamin D3 (25OHD3) and then by the kidney 1alphahydroxylase (1alphaOHase) to become 1,25dihydroxyvitamin D 3 (1,25(OH)2D3). 1,25(OH)2 D3 is a potent inhibitor of tumor growth in vitro and in vivo. Recent studies indicate that metabolic activation of 1,25(OH) 2D3 also occurs in cancer cells such as breast cancer. Consequently, the major objective of this project was to determine if tumoral 25OHD 3-1alphahydroxylase modulates any or all of the stages of breast tumor progression without inducing the hypercalcemic side effects of 1,25(OH) 2D3. For this purpose we used the PyVMT breast cancer mouse model in which the oncoprotein, polyomamiddle T antigen (PyMT) is under the control of mouse mammary tumor virus LTR (MMTV LTR). Mice exhibited tumors restricted to the mammary epithelium progressing to the various stages of breast cancer. Animals were treated with either vehicle, 25OHD3 (2000 pM/24h) or 1,25(OH)2D3 (12pM/24h). Mice treated with the vitamin D precursor, 25OHD3, exhibited a marked reduction in tumor onset and growth comparable to the 1,25(OH)2D3 treated group. Furthermore, biomarkers of tumor progression were markedly reduced in 25OHD3 and 1,25(OH)2D3 animals as compared to vehicle-treated animals. However, mean circulating calcium concentrations remained unchanged in 25OHD3 treated animals but increased significantly in 1,25(OH)2D3 treated animals as compared to controls. Tumoral levels of 1,25(OH)2D3 in mice treated with 25OHD3 were increased 79% in comparison to vehicle control mice. Additionally, 25OHD3 and 1,25(OH)2D 3 treated animals had a significant decrease in the mean number of lung metastases per animal as compared to vehicle treated control animals. This study therefore suggests an important autocrine role of 1alphaOHase expression in breast tumor cells. Furthermore, accumulation of intra-tumoral 1,25(OH) 2D3 in response to 25OHD3 administration strongly suggests that locally produced 1,25(OH)2D3 plays a significant role in restraining tumor growth without inducing the hypercalcemic side effects associated with 1,25(OH)2D3.

Thesis (Ph.D. in Toxicology) -- University of Colorado Denver, 2008. / Typescript. Includes bibliographical references (leaves 224-253). Free to UCD Anschutz Medical Campus. Online version available via ProQuest Digital Dissertations;

Thesis (Ph.D. in Biophysics & Genetics, Program in Molecular Biology) -- University of Colorado Denver, 2007. / Typescript. Includes bibliographical references (leaves 115-132). Free to UCD affiliates. Online version available via ProQuest Digital Dissertations;

Chick embryo fibroblasts and rat kidney cells infected in vitro with Rous Sarcoma viruses were treated with 3-deazaguanine (3-DG). The findings revealed that 3-DG inhibited virus-induced cellular transformation. Degree of inhibition is dependent on concentration and frequency of media change. 3-DG at the concentrations tested will not reverse transformed cells to the untransformed state and does not have marked effect on replication of viruses. Upon removal of 3-DG, its effect was shown to be reversible. Cell growth was generally retarded in medium containing 3-DG. When xanthosine and inosine were added to the medium, cell growth was unaffected, but it increased in guanosine.

No description available.

No description available.

As leucemias cromossomo Ph-positivas estão intimamente associadas à expressão da tirosina-quinase Bcr-Abl. Esta oncoproteína promove independência de fatores de crescimento, alterações na adesão e inibição da apoptose por mecanismos ainda não totalmente elucidados. O objetivo desse estudo foi avaliar a contribuição da atividade quinase de Bcr-Abl para seu potencial anti-apoptótico e identificar alterações moleculares envolvidas na transformação celular induzida por essa proteína. Nossos resultados sugerem que a resistência à apoptose não depende da manutenção constante da atividade tirosina-quinase de Bcr-Abl, tampouco da presença de proteínas fosforiladas em tirosina. A comparação do proteoma de células HL-60.vetor e HL-60.Bcr-Abl revelou que a presença de Bcr-Abl causa alterações profundas no padrão de expressão protéica. As proteínas afetadas estão associadas a diversos processos celulares, como adesão, transdução de sinais, proliferação e morte celular. Esses achados devem contribuir para a identificação de novos marcadores de prognóstico e alvos terapêuticos. / Ph chromosome-positive leukemias are closely associated with the expression of Bcr-Abl tyrosine kinase. This oncoprotein promotes growth factor independence, alters cell adhesion and confers resistance to apoptosis by mechanisms that are not fully understood. The aim of this study was to evaluate the contribution of Bcr-Abl kinase activity for its antiapoptotic potential and identify molecular alterations involved in Bcr-Abl-induced cell malignant transformation. Our results suggest that Bcr-Abl is not required to be constantly active to maintain the resistance to apoptosis and pY-containing proteins may not be responsible for the antiapoptotic effect of Bcr-Abl. The comparison between the proteome of HL-60.vector and HL-60.Bcr-Abl cells revealed that the presence of Bcr-Abl alters the expression of a great variety of proteins. The affected molecules are associated with several cellular processes, including cell adhesion, signal transduction, proliferation and cell death. Our findings might help the identification of new prognostic markers and therapeutic targets.

Les composés perfluorés (PFC) de formule chimique générale CF3-(CF2)n-SO3- ( sulfonates) ou CF3-(CF2)n-1-CO2- (acides) sont des polluants organiques émergents, dont la persistance, la bioaccumulation et la toxicité sont maintenant considérées préoccupantes au plan sanitaire et environnemental. L'objectif de notre recherche a été de mettre en évidence les effets cancérogènes in vitro et le mécanisme d'action impliqué lors de l'exposition pendant 7 jours de cellules embryonnaires de hamster Syrien (SHE) aux principaux représentants perfluorés, le sulfonate de perfluorooctane (PFOS), le perfluorooctanoate (PFOA), et à leur substitut, le sulfonate de perfluorobutane (PFBS). Le test de transformation cellulaire dans sa version standard ou selon un protocole de type initiation-promotion a permis de détecter les substances cancérogènes de profil initiateur ou promoteur de tumeur. La génotoxicité des PFCs a été explorée par le test Comet en conditions alcalines. PFOS a présenté un profil cancérogène non génotoxique de type initiateur aux concentrations de 0,37 et 3,7 µM (p<=0,01), coïncidant avec les concentrations sériques des travailleurs exposés au PFOS. L'activation des gènes PPARs a été observée après 7 jours d'exposition au PFOS, avec une induction plus importante et plus précoce (dès 24 heures d'exposition) du gène ppar-bêta/gamma aux concentrations transformantes (p<=0,05). PFOA appliqué seul n'induit pas la transformation néoplasique des cellules SHE. Par contre, il induit la transformation des cellules présensibilisées par un initiateur. Il agit selon un profil cancérogène non génotoxique de type promoteur de tumeur aux concentrations de 3,7 x 10-4 à 37 µM. Ces concentrations coïncident avec les concentrations sériques mesurées dans les populations professionnellement et non professionnellement exposées. PFBS ne s'est révélé ni initiateur, ni promoteur de tumeur. La mise en cause de ces PFCs dans l'augmentation des cancers de la vessie (pour le PFOS) et celui de la prostate (pour le PFOA) chez les travailleurs exposés ne peut être exclue / Perfluorinated compounds (PFCs) is a collective name for fluorinated surfactants and polymers with the general structure CF3-(CF2)n-SO3- (sulfonates) or CF3-(CF2)n-1-CO2- .(acids). This group is characterized by a high persistence, bioaccumulation and long term toxicity which are rising environmental and public health concerns. In the present work, we analyzed the in vitro carcinogenic potential of the two major PFCs, perfluorooctane sulfonate (PFOS), and perfluorooctanoic acid (PFOA), and their substitute, perfluorobutane sulfonate (PFBS). Cell transformation assays were carried out on Syrian hamster embryo (SHE) cells in a 7 day-treatment using the standard and the initiation-promotion protocols. Genotoxicity was tested using the comet assay. PFOS was not genotoxic on SHE cells, but it induced cell transformation at non cytotoxic concentrations 0,37 and 3,7 µM (p<=0,01). These concentrations coincided with serum PFOS concentrations measured in occupationally exposed workers. An increased expression of PPARs was registered after 7 days. The ppar-beta/gamma mRNA appeared to increase rapidly (24 hours after PFOS treatment) at concentrations closely related to cell transformation (p<=0,05). PFOA was inactive alone, but induced cell transformation of SHE cells pre-initiated with benzo(a)pyrene (BaP). Therefore PFOA was shown to act as a tumor promoter and a non genotoxic carcinogen at a large range of concentrations (3,7 x 10-4 à 37 µM). This range of concentrations covered seric concentrations in non-occupationally exposed and occupationally exposed populations. PFBS was negative alone and on BaP-pretreated SHE cells. For this reason, its use as a substitute for PFOS appears to be justified. To conclude, the cell transforming potenty of PFOS and PFOA denotes in vitro carcinogenic potential. Consequently, the hypothesis of their implication in human cancer recorded in occupationally exposed populations cannot be ruled out